{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-154170","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.567819+00:00","generated_at":"2026-05-18T09:51:20.863136+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptose defers interest payment on Hanmi loan to December 31, 2025","bullets":["Interest for Dec 21, 2024–Mar 31, 2025, originally due June 27, 2025, deferred to Dec 31, 2025.","Interest for Mar 31–Jun 30, 2025 also deferred to Dec 31, 2025.","Interest Deferral Agreement signed June 24, 2025 between Aptose and Hanmi.","Aptose is a clinical-stage precision oncology company developing tuspetinib for AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-154170","json":"https://secwatch.observer/filing/0001193125-25-154170.json","markdown":"https://secwatch.observer/filing/0001193125-25-154170.md","text":"https://secwatch.observer/filing/0001193125-25-154170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000119312525154170/0001193125-25-154170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000119312525154170/d68389d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:51:20.863136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}